Zanubrutinib
Brand name: Brukinsa
Rank #74 of 500 drugs by total cost
$256.8M
Total Cost
19,239
Total Claims
$256.8M
Total Cost
810
Prescribers
$13K
Cost per Claim
417
Beneficiaries
19,329
30-Day Fills
$317K
Avg Cost/Provider
24
Avg Claims/Provider
About Zanubrutinib
Zanubrutinib (sold as Brukinsa) was prescribed 19,239 times by 810 Medicare Part D providers in 2023, costing the program $256.8M. At $13K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 71 | Rosuvastatin Calcium (Rosuvastatin Calcium) | $264.9M | 11,259,701 |
| 72 | Risankizumab-Rzaa (Skyrizi Pen) | $259.7M | 12,539 |
| 73 | Venetoclax (Venclexta) | $259.6M | 28,191 |
| 74 | Zanubrutinib (Brukinsa) | $256.8M | 19,239 |
| 75 | Metoprolol Succinate (Metoprolol Succinate) | $256.3M | 12,847,535 |
| 76 | Dolutegravir Sodium (Tivicay) | $251.7M | 102,995 |
| 77 | Abemaciclib (Verzenio) | $242.2M | 16,125 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology